Universal Ibogaine has announced the appointment of a new CEO: Dr. Rami Batal. Batal is a veteran biopharmaceutical industry executive and a healthcare professional with impressive expertise and a background in mental health, specifically substance use disorders. Batal has spent his career in biomedical innovation, specifically biopharmaceutical research, development and commercialization of medicines for pain and central nervous system disorders (“CNS”). He has worked with numerous multinational pharmaceutical companies and biotech startups, including, most recently, Antibe Therapeutics (TSX:ATE), where he oversaw the commercial readiness of otenaproxesul, a phase 3 pain/osteoarthritis drug candidate, which was recently outlicensed to Nuance Pharma for the Greater China region. Prior to his time at Antibe, Batal served as vice president of medical innovation and vice president of medical research of Canopy Growth Corporation. He also cofounded CHI (“CHI”), a biotech company focused on cannabinoid research for biopharmaceutical purposes. Batal earned his doctorate in experimental medicine from McGill University and is licensed to practice pharmacy in Quebec. “Rami’s past experience in biopharmaceutical research, particularly in CNS, is exactly the leadership UI needs to advance our planned clinical research program with Health Canada for the use of ibogaine in addiction treatment, which is an integral part of our overall strategy to address the global and devastating opioid addiction crisis,” said Universal Ibogaine executive chairman Shayne Nyquvest in the press release.
To view the full press release, visit https://nnw.fm/0tvvI
About Universal Ibogaine Inc.
Universal Ibogaine is a privately held company formed in 2018 and based in Vancouver, British Columbia. UI is in the initial stages of implementing and financing its business plan, which aims at developing a global network of addiction treatment clinics and introducing ibogaine in a medical setting where authorized, for the interruption and ideally cessation of addiction to opioids, as well as other substances of abuse, such as alcohol and cocaine. For more information about the company, please visit www.IbogaineInc.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
